How to get it

2009 January Comparative Analysis of MesenchymalStem Cells from Bone Marrow,Umbilical Cord Blood, orAdipose Tissue. Mesenchymal stem cells (MSCs) represent a promising tool for new clinical concepts in supporting cellular therapy. READ

2014 January Human Umbilical Cord Mesenchymal Stem Cell Transplantation for theTreatment of Chronic DiscogenicLow Back Pain. Human umbilical cord tissue-derived mesenchymal stem cells (HUC-MSCs) contain stem cells and possess the ability to regenerate degenerative discs. READ

2014 May Umbilical cord mesenchymal stem cell transfusion ameliorated hyperglycemia inpatients with type 2 diabetes mellitus. Type 2 diabetes mellitus (T2DM) is a serious threat to human health and remains incurable. READ

2015 May Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells inpatients with type 2 diabetes. Type 2 diabetes (T2D) is characterized by progressive and inexorable β-cell dysfunction, leading to insulin deficiency. READ

2015 June Umbilical cord blood donation: public or private? Umbilical cord blood (UCB) is a graft source for patients with malignant or genetic diseases who can be cured by allogeneic hematopoietic cell transplantation (HCT), but who do not have an appropriately HLA-matched family or volunteer unrelated adult donor. READ

2015 July Transplantation of umbilical cord blood mononuclear cells increases levels ofnerve growth factor in the cerebrospinalfluid of patients with autism. We aimed to evaluate the levels of growth factors in the cerebrospinal fluid (CSF) of patients with autism after transplantation of umbilical cord blood mononuclear cells (CBMNCs). READ

2016 February Time related variations in stem cell harvesting of umbilical cord blood. Umbilical cord blood (UCB) contains hematopoietic stem cells and multipotent mesenchymal cells useful for treatment in malignant/nonmalignant hematologic-immunologic diseases and regenerative medicine. READ

2016 February Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by 656 centers in 47 countries to the 2014 survey. READ

2017 February Genetically re-engineered K562 cells significantly expand and functionallyactivate cord blood natural killer cells: Potential for adoptive cellularimmunotherapy Cord blood (CB) mononuclear cells were expanded with artificial antigen-presenting cells. READ

2017 April Umbilical Cord Blood Transplantation: Challengesand Future Directions. An exciting new development is the use of either autologous or unrelated UCBT for nontraditional applications (outside of oncology) in neurology, endocrinology, and cardiology, for diseases that have significant worldwide impact. READ

2017 April Autologous Cord Blood Infusions Are Safe andFeasible in Young Children with AutismSpectrum Disorder: Results of a Single‐CenterPhase I Open‐Label Trial. Despite advances in early diagnosis and behavioral therapies, more effective treatments for children with autism spectrum disorder (ASD) are needed. READ

2017 April A History of Cord Blood Banking andTransplantation. Cord blood is not just a “bag of blood stem cells,” and newer therapies are leveraging the activities of monocytes and other cells in the mix. READ

2017 June Anticancer cellular immunotherapies taken from umbilical cord blood. The lack of highly effective drugs in many malignancies has prompted scientific interest in the development of alternative treatment strategies. READ

2017 August Update on umbilical cord blood transplantation. Allogeneic hematopoietic cell transplant is a curative procedure for many patients with leukemia, lymphoma, myelodysplasia, myeloproliferative neoplasms, and genetic disorders. READ

2017 October Effect of Autologous Cord Blood Infusionon Motor Function and Brain Connectivity in Young Children with Cerebral Palsy:A Randomized, Placebo‐Controlled Trial. Cerebral palsy (CP) is a condition affecting young children that causes lifelong disabilities. Umbilical cord blood cells improve motor function in experimental systems via paracrine signaling. READ

2017 November The first decade of advanced cell therapy clinicaltrials using perinatal cells. Advanced cell therapy with perinatal cells is a new field that covers a wide range of diagnoses but where most of the trials are early Phase. READ

2017 November Cord Blood Banking for Potential Future Transplantation. This policy statement is intended to provide information to guide pediatricians, obstetricians, and other medical specialists and health care providers in responding to parents’ questions about cord blood donation and banking as well as the types (public versus private) and quality of cord blood banks. READ

2018 April Safety and Observations from a Placebo‐Controlled, Crossover Study to Assess Use of AutologousUmbilical Cord Blood Stem Cells to ImproveSymptoms in Children with Autism. The aim of this exploratory study was to assess the safety and clinical effects of autologous umbilical cord blood (AUCB) infusion in children with idiopathic autism spectrum disorder (ASD). READ

2018 May Allogeneic Umbilical Cord Blood Infusion for Adultswith Ischemic Stroke: Clinical Outcomes froma Phase I Safety Study. Stroke is a major cause of death and long‐term disability, affecting one in six people worldwide. READ

2018 July Cord Blood Infusion for Children With AutismSpectrum Disorder (Duke ACT). This is a single site, prospective, randomized, double-blind study of a single intravenous autologous or allogeneic, unrelated cord blood (CB) infusion in children ages 2-7 years with Autism Spectrum Disorder (ASD). READ

2018 July Repurposing the Cord Blood Bank for Haplobankingof HLA‐Homozygous iPSCs and TheirUsefulness to Multiple Populations. Although autologous induced pluripotent stem cells (iPSCs) can potentially be useful for treating patients without immune rejection, in reality it will be extremely expensive and labor‐intensive to make iPSCs to realize personalized medicine. READ

2018 August Safety of Autologous Umbilical Cord Blood Therapyfor Acquired Sensorineural Hearing Loss inChildren. Sensorineural hearing loss (SNHL) in children is associated with neurocognitive morbidity. The cause of SNHL is a loss of hair cells in the organ of Corti. READ

2018 August Advances in perinatal stem cells research: Aprecious cell source for clinical applications. Perinatal tissues possess numerous types of stem (stromal) cells, which are considered effective candidates for cell therapy. READ

2018 September Factors Influencing the rise ofUmbilical Blood Cell's Stem Cell Industry. The lack of highly effective drugs in many malignancies has prompted scientific interest in the development of alternative treatment strategies. READ

2018 September Indications for Utilization of Stored Umbilical Cord Blood. Since the first umbilical cord blood transplantation in 1988 for Fanconi’s anemia (1), umbilical cord blood has become a safe and dependable alternative donor graft source for use in allogeneic hematopoietic cell transplantation. READ

2018 September Factors Influencing the Umbilical Cord Blood StemCell Industry: An Evolving Treatment Landscape. Hematopoietic stem cell transplantation (HSCT) is common practice today for life threatening malignant and non‐malignant diseases of the blood and immune systems. READ

2018 November Current and future status of stem cell expansion. Decreased number of stem cells contained in a cord blood unit and early differentiation of stem cells once expanded have been two overarching challenges faced by the field. READ

2018 December Umbilical Cord‐Derived Mesenchymal Stromal Cells (MSCs) forKnee Osteoarthritis. The lack of highly effective drugs in many malignancies has prompted scientific interest in the development of alternative treatment strategies. READ

Scientific content reviewed by the Bioscience Institute Scientific Board. · Last updated 2019-05-17

The information on this page is for general education and does not replace a consultation with a physician.

This page in other languages: Italiano 中文

Clinical Trials

Request information

Cord blood and cord tissue at birth, adipose tissue at any age: cryopreservation in our GMP cryobank in San Marino since 2008.

Clinical Trials

Request information

Cord blood and cord tissue at birth, adipose tissue at any age: cryopreservation in our GMP cryobank in San Marino since 2008.

Connect with us on social